An open-label, phase II study indicated the efficacy of ICIs in PD-L1 positive (PD-L1 expression ≥1%) stage IV NSCLC with brain metastasis, with 29.7% of patients achieving a response [111]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.